title: Duration of prior vancomycin therapy and subsequent daptomycin treatment outcomes in methicillin-resistant Staphylococcus aureus bacteremia.
abstract: The association between varying durations of previous vancomycin therapy and subsequent daptomycin success rates was evaluated in a subset of patients with methicillin-resistant Staphylococcus aureus bacteremia from the Cubicin® Outcomes Registry and Experience 2005-2009 (n=159). Previous vancomycin exposure did not adversely affect daptomycin outcomes; success rates were 81% in patients treated with first-line daptomycin and 89%, 83%, and 88%, respectively, in patients with 1-3days, 4-6days, and ≥7days of previous vancomycin exposure (P=0.5).
authors.affiliation: Merck and Co., Kenilworth, NJ, USA. Electronic address: darren.culshaw@merck.com.
authors.forename: Darren
authors.initials: D
authors.lastname: Culshaw
authors.affiliation: Merck and Co., Kenilworth, NJ, USA.
authors.forename: Kenneth C
authors.initials: KC
authors.lastname: Lamp
authors.affiliation: Merck and Co., Kenilworth, NJ, USA.
authors.forename: Min J
authors.initials: MJ
authors.lastname: Yoon
authors.affiliation: Albany College of Pharmacy and Health Sciences, Albany, NY, USA.
authors.forename: Thomas P
authors.initials: TP
authors.lastname: Lodise
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D016470:Bacteremia / Q000188:drug therapy* / Q000382:microbiology; D017576:Daptomycin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D055624:Methicillin-Resistant Staphylococcus aureus / Q000302:isolation & purification*; D008875:Middle Aged; D012189:Retrospective Studies; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology; D013997:Time Factors; D016896:Treatment Outcome; D014640:Vancomycin / Q000627:therapeutic use*
chemical_list: D000900:Anti-Bacterial Agents; D014640:Vancomycin; D017576:Daptomycin
keywords: Bacteremia; Daptomycin; Methicillin-resistant Staphylococcus aureus; Treatment outcomes; Vancomycin